Hope is not a strategy. Evidence must drive it.
Science creates value only when medical strategy, regulation, trial design, execution, access, capital and leadership work as one system.
MB & Partners provides CMO-level ownership of that system—from the first development thesis through lifecycle evidence and controlled global execution.
Observe the rhythm. Anticipate the break. Act before value is lost.
Call us when a Phase I–IV development decision, lifecycle or Medical Affairs strategy, board-level clinical risk review, financing round or drifting trial cannot afford the wrong answer.
Clinical programmes fail at the interfaces.
The protocol may satisfy Clinical Development. The country plan may satisfy Operations. The comparator may satisfy Regulatory. The budget may satisfy Procurement. Yet the complete programme can still produce an answer that is late, unaffordable, uninterpretable or irrelevant to patients, payers and investors.
Functional competence is not system performance. MB&P brings medical, regulatory, patient, payer, commercial, operational, leadership and capital perspectives into one decision system.
From Cutting-Edge Clinical Strategy: The P-Value Did Not Kill the Drug ↗
One clinical-development system. Eight ways to enter it.
You may need one intervention. Your programme still needs one system. Each mandate begins with the problem you can see, but is examined in the context of the whole development architecture.
Fractional CMO & Medical Leadership
Accountable CMO-level ownership across clinical strategy, board decisions, medical governance, capital allocation and execution.
Clinical Development Strategy & Pivotal Trial Design
Define what must be learned, proven and decided before assumptions become locked into protocols, timelines and capital commitments.
Trial Rescue & Execution Governance
Reconstruct why the evidence system is drifting, restore decision rights and protect interpretability before an expensive but unusable conclusion.
Regulatory, HTA & Evidence Strategy
Align approval, reimbursement, patient value and future clinical relevance before pivotal assumptions become difficult to change.
Investor Due Diligence & Asset Development
Test whether the programme deserves more capital, which assumptions threaten value and what must change before financing, licensing or partnering.
Fundraising & Growth
Build the strategy, evidence and investor narrative needed to secure capital, licensing partners and the next stage of growth.
Medical Affairs & Lifecycle Development
Continue clinical development after launch through scientific authority, lifecycle evidence, external intelligence and insight-to-action governance.
Global Clinical Trial Execution
Translate the clinical architecture into countries, sites, vendors, quality, data and timelines through one governed hub-and-spoke delivery model.
One architecture. One contract. The right specialists behind it.
The client contracts with MB & Partners (MB&P) or Verum. We assemble and govern the regional CROs, clinical sites, laboratories, specialist vendors and healthcare partners required by the programme. One integrated plan, one risk and assumption register, one governance cadence and one escalation path connect strategy to delivery. This is the Network for Excellence in Clinical Trials And Research (NECTAR).
The spokes adapt to the programme. Accountability does not.
MB&P
Senior ownership of the development thesis, evidence architecture and cross-functional decisions that determine programme value.
Verum
The accountable medical, project, quality and sponsor-facing execution hub through which the client contracts.
NECTAR
Qualified regional CROs, sites and specialist capabilities selected for the programme and governed through the same operating logic.
A disciplined sequence from uncertainty to controlled execution.
Diagnose
Map the evidence, execution and governance risks that threaten the next decision.
Redesign
Correct the architecture before weak assumptions become embedded in cost and timelines.
Align
Converge medical, regulatory, payer, operational, leadership and capital logic.
Execute
Govern delivery until the evidence remains interpretable at database lock and beyond.
Representative outcomes. Not promises.
Selected programme and partner-network outcomes. These figures show what disciplined design and governance can achieve; they are not universal guarantees. 30+ years · 100+ studies · Phase I–IV and lifecycle evidence · five-continent experience.
faster FPI
Start-up acceleration through governed hub-and-spoke execution.
lower screen-fail rate
Better fit between protocol assumptions, site reality and patient selection.
continents
Coordinated multi-region execution under one governance logic.
Approval is a milestone. Clinical development continues.
A programme designed only for approval is already under-designed. Before launch, evidence must support regulatory claims, access, adoption, differentiation and the next capital decision. After launch, the product enters clinical life: comparative value, safety, place in therapy and future evidence questions become real.
Medical Affairs is not a marketing support layer. It is the continuation of clinical development across the product lifecycle.
- Scientific authority: own the narrative and defend evidence quality.
- Lifecycle development: govern RWE, IIS, registries, pragmatic studies and evidence gaps.
- Capital discipline: connect evidence gates to investment, partnering and portfolio decisions.
From Precision in Practice: Technically Strong. Impact Low. Why Medical Affairs Must Lead ↗
The proposal is not the price.
A low initial budget can be built on best-case recruitment, underestimated activity, fragmented responsibilities and exclusions that become chargeable only after execution begins. The headline price wins the procurement decision. The assumptions determine the final spend.
Country selection is not a logistics choice. It changes patient access, site capability, recruitment, endpoint variability, duration, cost, generalisability and payer relevance. The country is part of the trial design.
- Pressure-test first: challenge the protocol and feasibility before pricing delivery.
- Make interfaces visible: define responsibilities, exclusions and escalation before signature.
- Use the smallest sufficient system: one accountable hub, fit-for-purpose specialists and no unnecessary infrastructure.
The “Hybrid CRO Model” Is Misnamed ↗
The Estimand Under Stress ↗
Three academies. Three entry doors. One discipline.
People enter through the problem they recognise. Some begin with leadership. Some begin with Medical Affairs. Others begin with the complete clinical-development system. Each academy stands on its own. Together they reveal why functional expertise alone cannot govern a complex life-science outcome.
Areté Leadership Academy
Judgement, truth-seeking, responsibility and leadership under uncertainty. It shows how leadership determines whether difficult evidence decisions are made early enough.
Clinical Development Excellence Academy
The integrative pathway built from the Clinical Development Excellence Canon: science, strategy, evidence, execution, access, Medical Affairs, leadership and lifecycle learning.
Medical Affairs Strategy Academy
Scientific authority, lifecycle evidence, Field Medical intelligence and insight-to-action. It repositions Medical Affairs as post-launch clinical development rather than promotional support.
Recognised for what the system requires.
The recurring pattern is unusual breadth: senior medical judgement, operational realism, originality of thought and the ability to turn complexity into accountable decisions.
Jonas Fischer
CEO, Immungenetics AG
“He contributed to the development of the Phase II study design and protocol submission, was closely involved in selecting subcontractors, and supported us in achieving scientific advice from EMA.”
Ram Yeleswarapu
Former President & CEO, Navitas Life Sciences
“He quickly earned the reputation of the ‘go-to’ expert among our teams. He would roll up his sleeves and convert strategy to action by working on deliverables.”
Steve Galen, PhD
Owner, Galen FP Solutions; former Global Head, Clinical Division, Navitas Life Sciences
“A highly respected medical expert who also has deep and practical operational insight. Physicians with both capabilities are extremely rare and valuable.”
Henry J. Riordan, PhD
Chief Development Officer, Worldwide Clinical Trials
“He holds himself to the highest standards for excellence, rigor and integrity, and has always been a team player acutely aware of his role and team dynamics.”
Angelico Carta, MD
President & Co-Founder, Worldwide Clinical Trials
“His contribution, commitment and professionalism across those five years was truly outstanding; always well prepared, he supported many different programs and sponsors with high quality.”
Flavia Christina Ladwig Robles
CEO, Vortex Pharma Solution ApS
“He navigates medical, safety, regulatory, data management, biostatistics and clinical operations, making him an ideal stakeholder for finding fit-for-purpose innovative solutions.”
Raymond M. M. Hupperts, MD, PhD
Professor of Multiple Sclerosis, Maastricht University Medical Center / Academic MS Center Limburg
“His broad knowledge of MS clinical-study characteristics makes him an expert in setting up trial design and methodology. His knowledge of statistics regarding trial outcome interpretations is of high academic level.”
Jon Bastow
Healthcare specialist & strategic adviser
“He was a vital bridge between the country-based medical teams and head office. He led and shaped the thinking around an important study across Europe, Latin America and Asia.”
Mauro Manconi, MD, PhD
Professor of Neurology; Head, Sleep & Epilepsy Center, Neurocenter of Southern Switzerland
“He stands out among my colleagues thanks to his originality of thinking, the breadth of his clinical and scientific knowledge and the consistent high quality of his work.”
Mariola Dymowska, MD
Former Senior Medical Director, argenx; former Global Lead, Debiopharm
“He brings not only strategic thinking, but a very pragmatic problem-solving approach. No doubt he is an expert in clinical research — both scientifically and operationally.”
Tomislav Babic, MD, PhD
Professor of Clinical Neurology; former VP Neuroscience Franchise, Worldwide Clinical Trials
“He contributed to the development of proposals, including innovative approaches, and delivered within tight timelines with strong business acumen for both the CRO and the client.”
Kohkan Shamsi, MD, PhD
Principal & Co-Founder, RadMD
“He was instrumental in completing the studies and FDA submission. He brings not only medical expertise but also provides strategic guidance to the team with a pragmatic and solution-oriented approach.”
Bilal Bham
Founder & Principal Consultant, Amodaia
“I know that when I am working on a project with him, I am with someone I can trust to deliver the best-in-class quality, and be refreshingly honest and insightful.”
Antoine Aballéa
Project Manager, Named Patient Programs, WEP Clinical
“He consistently delivered high quality feedback on the projects, and assisted our affiliates at every opportunity. From the very first day I could rely on his advice and expertise.”
Maria Lopez-Bresnahan, MD, MBA, FAAN
Head of Clinical Development, Neuroscience, Bristol Myers Squibb
“Manolo Beelke is an experienced biotechnology professional. He is highly industrious, excellent at finding solutions, and results driven, always aiming to achieve timelines and milestones.”
Thomas F. Feiner, QEEG-D
Founder & CEO, Institute for EEG-Neurofeedback (IFEN)
“Dr. Beelke has helped our Institute with a lot of brilliant analysis and ideas in the field of EEG and QEEG. With his outstanding knowledge and experience we are happy to have his support in ongoing studies.”
What decision cannot afford to be wrong?
Bring one live decision, the next hard milestone and the time available. The first conversation will identify where the programme is most exposed, whether focused intervention can create material value and what the shortest credible next step should be.
The cost of senior judgement is visible. The cost of the wrong decision usually appears later.
